Feedback
Settings

Settings

Goto Application

4,721 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(NIDVTARKFBZMOT-PEBGCTIMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 473
1.WO/2025/255556ENHANCED TARGETED PSEUDOURIDYLATION WITH SMALL NUCLEAR RNAS
WO - 11.12.2025
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/032791 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor YEO, Eugene
This disclosure provides methods and compositions to increase the efficiency of targeted coding RNA pseudouridylation by H/ACA snoRNA, by localizing the H/ACA snoRNA more to the nucleoplasm where pre-mRNAs are transcribed and processed into mature mRNAs versus the nucleolus, where H/ACA snoRNAs natively modify ribosomal RNAs.
2.WO/2025/255393HERPES SIMPLEX VIRUS ANTIGEN BINDING AGENTS FOR MITIGATION OF HERPES SIMPLEX VIRUS ASSOCIATED DISEASE
WO - 11.12.2025
Int.Class C07K 16/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
 Appl.No PCT/US2025/032531 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor COHEN, Gary H.
Provided herein are compositions for the prevention and treatment of genital herpes, comprising antigen binding agents to herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, ribonucleic acids (RNAs) encoding these antigen binding agents, and methods of use thereof.
3.WO/2025/252759TRANSIENT EXPRESSION BY LIPID NANOPARTICLE FORMULATIONS
WO - 11.12.2025
Int.Class C12N 15/88
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
88using microencapsulation, e.g. using liposome vesicle
 Appl.No PCT/EP2025/065387 Applicant BIO-SOURCING Inventor BOURCY, Morgane
The present invention relates to means and methods for transient expression of a protein of interest by non-viral formulations such as lipid nanoparticle (LNP) formulations.
4.WO/2025/250703SYNTHETIC ENGINEERED RN A MOLECULES AND RELATED METHODS
WO - 04.12.2025
Int.Class C12N 15/85
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
 Appl.No PCT/US2025/031277 Applicant RNAV8 BIO, INC. Inventor BIELECKI, Kristine
Provided herein are heterologous engineered mRNA molecules; and methods of making and using said synthetic, engineered niRNAs to increase expression profiles.
5.WO/2025/250534T CELL TARGETS FOR TUBERCULOSIS VACCINES
WO - 04.12.2025
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
 Appl.No PCT/US2025/031027 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor DAVIS, Mark M.
The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.
6.WO/2025/250751CIRCULAR RNA COMPOSITIONS AND METHODS
WO - 04.12.2025
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
 Appl.No PCT/US2025/031358 Applicant ORNA THERAPEUTICS, INC. Inventor EMMANUEL, Akinola
Circular RNA, along with related compositions, methods, and precursor RNA, are described herein. In some embodiments, the composition comprises a transfer vehicle and a circular RNA comprising a 3' self-spliced exon segment, a translation initiation element (TIE), an expression sequence encoding a chimeric antigen receptor (CAR), and a 5' self-spliced exon segment. In some embodiments, the transfer vehicle comprises an ionizable lipid disclosed herein. In some embodiments, the circular RNA and/or composition thereof has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life as compared to linear RNA. Also presented herein are methods and compositions for the manufacture and preparation of circularized RNAs, along with methods of administering said circular RNAs and related compositions to a subject in need thereof for treatment or prevention purposes.
7.WO/2025/250677COMPOSITIONS AND METHODS FOR CORRECTION OF TREX1 MUTATIONS
WO - 04.12.2025
Int.Class C12N 15/52
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
52Genes encoding for enzymes or proenzymes
 Appl.No PCT/US2025/031247 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor MINER, Jonathan
Compositions and methods for correction of RVCL-causing mutations in a TREX1 gene are provided.
8.WO/2025/242026CANCER VACCINES AND USES THEREOF
WO - 27.11.2025
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/095665 Applicant EVEREST MEDICINES (CHINA) CO., LTD. Inventor XIE, Liang
Provided herein are nucleic acids, pharmaceutical compositions and vaccines that express two or more cancer antigens. Also provided herein are methods for treating a cancer.
9.20250360203MRNA COMPOSITION FOR REGULATING MRNA TRANSLATION COMPRISING MRNA AND ANTISENSE OLIGONUCLEOTIDE COMPLEMENTARY TO PORTION OF THE MRNA
US - 27.11.2025
Int.Class A61K 39/385
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
385Haptens or antigens, bound to carriers
 Appl.No 19214376 Applicant KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor Yong Woong JUN

Disclosed is an mRNA composition containing: an mRNA sequence comprising, in order from 5′ to 3′, a 5′ cap region, a 5′ UTR region, a start codon region, a 3′ UTR region, and a poly (A) tail region; and an antisense oligonucleotide containing a region complementary to the 5′ cap region. The mRNA composition containing the mRNA sequence and the antisense oligonucleotide containing a region complementary to the 5′ cap region of the mRNA sequence may regulate the translation rate of the mRNA, enables selective protein expression based on the type of nucleotide modification and DNA repair mechanism, and may improve the stability of the mRNA against RNA-degrading proteins, thereby improving the stability and efficiency of mRNA vaccines or therapeutics.

10.WO/2025/245111IMMUNORECEPTOR TARGETING PROTEINS AND RELATED METHODS
WO - 27.11.2025
Int.Class C07K 14/705
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
 Appl.No PCT/US2025/030194 Applicant FLAGSHIP PIONEERING INNOVATIONS VII, LLC Inventor BANDUKWALA, Hozefa Saifuddin
Provided herein are immunoreceptor targeting proteins and compositions (e.g., pharmaceutical compositions) comprising the same; as well as methods of making the immunoreceptor targeting proteins and compositions. The immunoreceptor targeting proteins provided herein are useful in pharmaceutical compositions and methods of use (including, e.g., binding to (e.g., thereby targeting) cells expressing CD30L, inhibiting binding or reducing (e.g., preventing) of one or more TNSRSF member to one or more TNFLSF member (e.g., binding of CD30L to CD30).
# -